AR078415A1 - Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen - Google Patents

Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Info

Publication number
AR078415A1
AR078415A1 ARP100102230A ARP100102230A AR078415A1 AR 078415 A1 AR078415 A1 AR 078415A1 AR P100102230 A ARP100102230 A AR P100102230A AR P100102230 A ARP100102230 A AR P100102230A AR 078415 A1 AR078415 A1 AR 078415A1
Authority
AR
Argentina
Prior art keywords
formula
compound
group
give rise
reacted
Prior art date
Application number
ARP100102230A
Other languages
English (en)
Inventor
Marie-Odile Vallez
Philippe Jubault
Philippe Gloanec
Philippe Mennecier
Tony Verbeuren
Jean-Charles Quirion
Alain Rupin
Nicolas Boyer
Nanteuil Guillaume De
Jean-Gilles Parmentier
Anne-Francoise Guillouzic
Original Assignee
Inst Nat Sciences Appliq
Servier Lab
S Ct Nat De La Rech Scient C N R
Univ Rouen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sciences Appliq, Servier Lab, S Ct Nat De La Rech Scient C N R, Univ Rouen filed Critical Inst Nat Sciences Appliq
Publication of AR078415A1 publication Critical patent/AR078415A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Compuestos de formula (1) en la que R1 representa un átomo de hidrogeno o un grupo de formula COR4, o bien R1 representa un grupo de formula (A); R2 representa un grupo de formula NR5R6, o bien R2 representa un grupo heterocíclico nitrogenado, arilo o heteroarilo, R3 representa un átomo de hidrogeno o un grupo alquilo, m representa un numero entero comprendido entre 1 y 6, n representa 0, 1 o 2, sus isomeros opticos, así como sus sales de adicion a un ácido farmacéuticamente aceptable. Medicamentos. Reivindicacion 9: Procedimiento de síntesis de los compuestos de formula (1) segun la reivindicacion 1 a partir del compuesto de formula (2) en la que n representa 0, 1, o 2, y G representa un grupo protector de la funcion carboxi, que se pone a reaccionar con un compuesto de formula (3) X-(CH2)m-R'2 en la que X representa un átomo de halogeno o un grupo triflato, tosilato o mesilato, m representa un numero entero comprendido entre 1 y 6, y R'2 representa un grupo de formula NR'5R'6 en la que R'5 y R'6, idénticos o diferentes, representan cada uno un grupo protector de la funcion amino o un grupo alquilo C1-6 lineal o ramificado, o bien R'2 representa un grupo heterocíclico nitrogenado sustituido opcionalmente con un grupo protector de la funcion amino o bien R'2 representa un grupo arilo o heteroarilo, para dar lugar al compuesto de formula (4) en la que R'2, G, m y n son tales como se han definido anteriormente, que se somete a un agente reductor de la funcion oxo, para dar lugar a un compuesto de formula (5) en la que n representa 0, 1 o 2, y G, m y n son tales como se han definido anteriormente, que se pone a reaccionar con cloruro de mesilo, cloruro de tosilo, anhídrido tríflico o un reactivo de halogenacion, para dar lugar al compuesto de formula (6) en la que R'2, G, m y n son tales como se han definido anteriormente, y X representa un grupo mesilato, tosilato, triflato o un átomo de halogeno, del que se separan los diastereoisomeros, cuando se desea obtener un compuesto de formula (1) en la forma de un unico diastereoisomero, y que se hace reaccionar con un compuesto de formula (7) MS-(CO)-R'1 en la que M representa potasio, sodio o litio, y R'1 representa un grupo alquilo o arilo, para dar lugar al compuesto de formula (8) en la que R'1, R'2, G, m y n son tales como se han definido anteriormente, del que se separan los enantiomeros por cromatografía quiral, cuando se desea obtener un compuesto de formula (1) en la forma de un unico enantiomero, y del que se desprotegen, llegado el caso, las funciones tiol, amino y carboxi, para dar lugar al compuesto de formula (1), que se pone a reaccionar, cuando se desea obtener una sal de adicion del compuesto de formula (1) a un ácido farmacéuticamente aceptable, con el ácido correspondiente. Reivindicacion 11: Composicion farmacéutica que contiene un compuesto de formula (1) segun una cualquiera de las reivindicaciones 1 a 8, en combinacion con uno o varios excipientes o vehículos inertes, no toxicos, farmacéuticamente aceptables.
ARP100102230A 2009-06-26 2010-06-24 Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen AR078415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903111A FR2947266B1 (fr) 2009-06-26 2009-06-26 Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR078415A1 true AR078415A1 (es) 2011-11-09

Family

ID=41594318

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102230A AR078415A1 (es) 2009-06-26 2010-06-24 Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Country Status (28)

Country Link
US (1) US8309341B2 (es)
EP (1) EP2272826A1 (es)
JP (1) JP5238757B2 (es)
KR (1) KR101187394B1 (es)
CN (1) CN101928241A (es)
AP (1) AP2010005304A0 (es)
AR (1) AR078415A1 (es)
AU (1) AU2010202563A1 (es)
BR (1) BRPI1001935A2 (es)
CA (1) CA2707647A1 (es)
CL (1) CL2010000694A1 (es)
CO (1) CO6300113A1 (es)
CR (1) CR11494A (es)
CU (1) CU20100133A7 (es)
EA (1) EA017867B1 (es)
EC (1) ECSP10010292A (es)
FR (1) FR2947266B1 (es)
GT (1) GT201000184A (es)
IL (1) IL206405A0 (es)
MA (1) MA32340B1 (es)
MX (1) MX2010007070A (es)
NI (1) NI201000111A (es)
NZ (1) NZ586444A (es)
PE (1) PE20110022A1 (es)
TW (1) TWI380813B (es)
UY (1) UY32702A (es)
WO (1) WO2010149888A1 (es)
ZA (1) ZA201004398B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109467506B (zh) * 2017-09-07 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
US4385062A (en) * 1980-01-09 1983-05-24 Gruppo Lepetit S.P.A. 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents
JPS5750955A (en) * 1980-09-12 1982-03-25 Hokko Chem Ind Co Ltd Oxime carbamate derivative and insecticide
JPH0565258A (ja) * 1991-07-03 1993-03-19 Nippon Bayeragrochem Kk 酢酸アニリド誘導体および除草剤
KR950701929A (ko) * 1992-05-29 1995-05-17 제이코버스 코넬리스 레이서 비정상적인 칼슘 및 인산염 대사를 치료하기 위한 황-함유 포스포네이트 화합물(sulfur-containing phosphonate compounds for treating abnormal calcium and phosphate metabolism)
BR0113289A (pt) * 2000-08-17 2003-06-17 Pfizer Imidazóis substituìdos como inibidores de tafia
KR100954651B1 (ko) * 2002-03-21 2010-04-27 바이엘 쉐링 파마 악티엔게젤샤프트 혈장 카르복시펩티드분해효소 ｂ 억제제
AU2002349247A1 (en) * 2002-10-04 2004-04-23 Pentapharm Ag Substrate for tafi (a)
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
MA32340B1 (fr) 2011-06-01
TWI380813B (zh) 2013-01-01
NZ586444A (en) 2011-09-30
ECSP10010292A (es) 2011-06-30
FR2947266A1 (fr) 2010-12-31
JP5238757B2 (ja) 2013-07-17
EA201000867A1 (ru) 2010-12-30
ZA201004398B (en) 2011-03-30
CR11494A (es) 2010-09-13
MX2010007070A (es) 2011-01-05
EA017867B1 (ru) 2013-03-29
AP2010005304A0 (en) 2010-06-30
AU2010202563A1 (en) 2011-01-20
US20100330064A1 (en) 2010-12-30
FR2947266B1 (fr) 2011-06-17
CO6300113A1 (es) 2011-07-21
TW201105322A (en) 2011-02-16
WO2010149888A1 (fr) 2010-12-29
BRPI1001935A2 (pt) 2012-03-06
KR20110000516A (ko) 2011-01-03
IL206405A0 (en) 2010-12-30
GT201000184A (es) 2012-04-30
UY32702A (es) 2010-12-31
EP2272826A1 (fr) 2011-01-12
CN101928241A (zh) 2010-12-29
CL2010000694A1 (es) 2011-05-06
CU20100133A7 (es) 2012-02-15
KR101187394B1 (ko) 2012-10-02
CA2707647A1 (fr) 2010-12-26
US8309341B2 (en) 2012-11-13
JP2011006416A (ja) 2011-01-13
NI201000111A (es) 2010-12-17
PE20110022A1 (es) 2011-02-04

Similar Documents

Publication Publication Date Title
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR059767A1 (es) Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer.
AR061739A1 (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR091790A1 (es) Derivados de isoquinolin-1-ona y sus usos
ME00962B (me) Benzimidazolski derivati
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR081333A1 (es) Metodo para preparar derivados de cicloalquilcarboxamidoindol, en particular (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida, compuestos intermediarios de dicha sintesis y metodo para prepararlos.
AR072488A1 (es) Derivados heterociclicos de 1,2,4-triazol, agonistas de receptores beta 2 adrenergicos y antagonistas muscarinicos colinergicos, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de afecciones respiratorias, inflamatorias y alergicas.
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR058073A1 (es) Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
AR078756A1 (es) Moduladores alostericos positivos (map)
AR082004A1 (es) Compuestos de fusion de piridina
CL2011002287A1 (es) Compuestos derivados de 8-fenoxi-1,1-dioxido-2,3,4,5-tetrahidro-1,2,5-benzotiadiazepina, moduladores de receptores ampa y nmda; composicion farmaceutica; procedimiento de prepapacion; y su uso para tratar enfermedades neurodegenerativas progresivas, alzheimer, parkinson, corea de huntington, entre otras; compuesto intermediario.
PE20140968A1 (es) Derivados de benzamida sustituida
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PA8614201A1 (es) Derivados de disulfuro, sulfuro, sulfoxido y sulfona de azucares ciclicos y sus usos
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY30933A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones farmacéuticas que contienen tales compuestos y aplicaciones.
AR078415A1 (es) Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR074593A1 (es) Benzotiazol amidas para la deteccion del peptido beta amiloide
AR061560A1 (es) Derivados de fenil-metanona sustituidos, proceso de obtencion y medicamentos que los contienen.
AR052276A1 (es) Proceso para preparar compuestos aromaticos biciclicos
AR045459A1 (es) Tiofenos sustituidos y usos de los mismos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal